Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 2
1965 3
1971 2
1973 1
1974 2
1975 1
1976 1
1977 3
1978 3
1979 3
1981 3
1983 4
1984 5
1985 1
1986 2
1987 4
1988 3
1989 1
1990 4
1991 5
1992 1
1993 7
1994 12
1995 9
1996 7
1997 14
1998 16
1999 25
2000 49
2001 42
2002 63
2003 90
2004 129
2005 127
2006 118
2007 125
2008 190
2009 209
2010 257
2011 268
2012 292
2013 352
2014 366
2015 380
2016 348
2017 386
2018 376
2019 372
2020 452
2021 507
2022 472
2023 457
2024 504
2025 51

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,373 results

Results by year

Filters applied: . Clear all
Page 1
MDM2 and MDMX promote ferroptosis by PPARα-mediated lipid remodeling.
Venkatesh D, O'Brien NA, Zandkarimi F, Tong DR, Stokes ME, Dunn DE, Kengmana ES, Aron AT, Klein AM, Csuka JM, Moon SH, Conrad M, Chang CJ, Lo DC, D'Alessandro A, Prives C, Stockwell BR. Venkatesh D, et al. Among authors: moon sh. Genes Dev. 2020 Apr 1;34(7-8):526-543. doi: 10.1101/gad.334219.119. Epub 2020 Feb 20. Genes Dev. 2020. PMID: 32079652 Free PMC article.
Rapidly Progressive Erythroderma.
Moon S, Israeli A, Daze R. Moon S, et al. Am Fam Physician. 2022 Jan 1;105(1):75-76. Am Fam Physician. 2022. PMID: 35029947 Free article. No abstract available.
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Jones RH, Casbard A, Carucci M, Cox C, Butler R, Alchami F, Madden TA, Bale C, Bezecny P, Joffe J, Moon S, Twelves C, Venkitaraman R, Waters S, Foxley A, Howell SJ. Jones RH, et al. Among authors: moon s. Lancet Oncol. 2020 Mar;21(3):345-357. doi: 10.1016/S1470-2045(19)30817-4. Epub 2020 Feb 5. Lancet Oncol. 2020. PMID: 32035020 Free PMC article. Clinical Trial.
The Diabetes Technology Society Error Grid and Trend Accuracy Matrix for Glucose Monitors.
Klonoff DC, Freckmann G, Pleus S, Kovatchev BP, Kerr D, Tse CC, Li C, Agus MSD, Dungan K, Voglová Hagerf B, Krouwer JS, Lee WA, Misra S, Rhee SY, Sabharwal A, Seley JJ, Shah VN, Tran NK, Waki K, Worth C, Tian T, Aaron RE, Rutledge K, Ho CN, Ayers AT, Adler A, Ahn DT, Aktürk HK, Al-Sofiani ME, Bailey TS, Baker M, Bally L, Bannuru RR, Bauer EM, Bee YM, Blanchette JE, Cengiz E, Chase JG, Y Chen K, Cherñavvsky D, Clements M, Cote GL, Dhatariya KK, Drincic A, Ejskjaer N, Espinoza J, Fabris C, Fleming GA, Gabbay MAL, Galindo RJ, Gómez-Medina AM, Heinemann L, Hermanns N, Hoang T, Hussain S, Jacobs PG, Jendle J, Joshi SR, Koliwad SK, Lal RA, Leiter LA, Lind M, Mader JK, Maran A, Masharani U, Mathioudakis N, McShane M, Mehta C, Moon SJ, Nichols JH, O'Neal DN, Pasquel FJ, Peters AL, Pfützner A, Pop-Busui R, Ranjitkar P, Rhee CM, Sacks DB, Schmidt S, Schwaighofer SM, Sheng B, Simonson GD, Sode K, Spanakis EK, Spartano NL, Umpierrez GE, Vareth M, Vesper HW, Wang J, Wright E, Wu AHB, Yeshiwas S, Zilbermint M, Kohn MA. Klonoff DC, et al. Among authors: moon sj. J Diabetes Sci Technol. 2024 Nov;18(6):1346-1361. doi: 10.1177/19322968241275701. Epub 2024 Oct 6. J Diabetes Sci Technol. 2024. PMID: 39369312
6,373 results